Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration

NCT04101877 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT04101877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04101877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Lead sponsor
Vastra Gotaland Region
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 3, 2020
Completion date
May 31, 2027
Enrollment
402 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration